Investors
Where Innovation Meets Impact.
AI-Powered Platforms Transforming Digital Health and Driving Shareholder Value
Why Invest in AIML?
CSE: AIML
OTCQB: AIMLF
FWB: 42FB
We are pioneering the future of health intelligence by developing and commercializing advanced AI-driven technologies that unlock powerful biometric insights
Backed by a growing portfolio of proprietary technologies and a world-class leadership team, AIML is committed to delivering long-term value to shareholders while improving health outcomes across global markets.
Press Releases
Read more in Archive
January 8, 2026
AIML subsidiary NeuralCloud Solutions Inc., Signs Non-Binding Commercial Term Sheet with Lakeshore Cardiology to Deploy CardioYield™ for AI-Powered Holter Analysis
Read More
January 7, 2026
AIML Appoints Erik Suokas as Chief Operating Officer to Accelerate Commercial Execution and Operational Scale
Read More
December 30, 2025
AIML Announces the Conclusion of Consulting Agreement and Leadership Transition for President & Chief Commercial Officer
Read More
December 16, 2025
Join AIML’s Live Shareholder Update with Chairman & CEO Paul Duffy
Read More
December 9, 2025
AIML subsidiary NeuralCloud Solutions Signs Commercial Term Sheet with Culminate H Labs to Deploy MaxYield™ and Insight360™ into INTRINSICA's DNA-Guided Biofeedback Wellness Ecosystem
Read More
December 2, 2025
AIML subsidiary NeuralCloud Enters Pilot with Cornerstone Physiotherapy to Deploy MaxYield™ and Insight360™ for Elite Athlete Cardiac Performance Testing
Read More
Corporate Governance
Board of Directors
Financials
Read more on CSE
Read more
Charters & Policies
Company Structure
253.9
Million
Shares Outstanding
16
Million
Options
190.7
Million
Warrants Outstanding
460.6
Million
Fully Diluted